BR112017015499A2 - ?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana? - Google Patents

?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana?

Info

Publication number
BR112017015499A2
BR112017015499A2 BR112017015499A BR112017015499A BR112017015499A2 BR 112017015499 A2 BR112017015499 A2 BR 112017015499A2 BR 112017015499 A BR112017015499 A BR 112017015499A BR 112017015499 A BR112017015499 A BR 112017015499A BR 112017015499 A2 BR112017015499 A2 BR 112017015499A2
Authority
BR
Brazil
Prior art keywords
destroying
treating
compositions
composition
methods
Prior art date
Application number
BR112017015499A
Other languages
English (en)
Inventor
Mandel Arkady
Original Assignee
Theralase Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theralase Tech Inc filed Critical Theralase Tech Inc
Publication of BR112017015499A2 publication Critical patent/BR112017015499A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições da invenção incluem glicoproteínas, tais como transferrina, e complexos de coordenação à base de metal, que são preferivelmente compostos quimoterapêuticos e mais preferivelmente compostos fotodinâmicos sintonizáveis. como composições são úteis como agentes de diagnóstico in vivo, e como agentes terapêuticos para tratar ou prevenção de doenças incluindo aquelas que envolvem células hiperprolifereantes em sua etiologia, tais como câncer. composições da invenção são adicionalmente capazes de destruir células microbiais, tais como bactérias, fungos, e protozoários, e destruir vírus.
BR112017015499A 2015-01-19 2016-01-19 ?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana? BR112017015499A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105080P 2015-01-19 2015-01-19
US201562166120P 2015-05-25 2015-05-25
PCT/IB2016/050253 WO2016116859A1 (en) 2015-01-19 2016-01-19 Metal-glycoprotein complexes and their use as chemotherapeutic compounds

Publications (1)

Publication Number Publication Date
BR112017015499A2 true BR112017015499A2 (pt) 2018-01-30

Family

ID=56406990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015499A BR112017015499A2 (pt) 2015-01-19 2016-01-19 ?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana?

Country Status (7)

Country Link
US (1) US9737565B2 (pt)
EP (1) EP3247397B1 (pt)
CN (2) CN117159705A (pt)
BR (1) BR112017015499A2 (pt)
CA (1) CA2974329C (pt)
RU (1) RU2742981C2 (pt)
WO (1) WO2016116859A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111701144B (zh) 2015-07-28 2023-03-21 诺欧生物有限责任公司 用于对一氧化氮的光疗调节的***和方法
US10335608B2 (en) * 2016-04-20 2019-07-02 Theralase Technologies, Inc. Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
US10994077B2 (en) 2016-07-21 2021-05-04 Tandem Diabetes Care, Inc. Enhanced confirmations for touchscreen infusion pump
CA3062883C (en) * 2017-05-11 2024-04-02 Theralase Biotech, Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
US10781226B2 (en) 2017-10-19 2020-09-22 Texas State University Photoactivatable cancer prodrug
CN107812189B (zh) * 2017-11-03 2020-12-08 南京师范大学 一种主动靶向特定肿瘤细胞的竹红菌素纳米制剂及其制备方法和应用
CA3038108A1 (en) * 2018-03-26 2019-09-26 Theralase Technologies, Inc. Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy
US11986666B2 (en) 2020-03-19 2024-05-21 Know Bio, Llc Illumination devices for inducing biological effects
US12011611B2 (en) 2020-03-19 2024-06-18 Know Bio, Llc Illumination devices for inducing biological effects
US11147984B2 (en) 2020-03-19 2021-10-19 Know Bio, Llc Illumination devices for inducing biological effects
CN112544613B (zh) * 2020-12-25 2022-08-16 武汉睿健医药科技有限公司 一种多能干细胞冻存液、其应用及冻存方法
US11654294B2 (en) 2021-03-15 2023-05-23 Know Bio, Llc Intranasal illumination devices
CN114558148B (zh) * 2022-03-18 2024-03-08 郑州大学 一种肿瘤“开关型”纳米光疗***的制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404334A4 (en) 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER
US20030103995A1 (en) 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
US6962910B2 (en) 2002-02-01 2005-11-08 Virginia Tech Intellectual Properties, Inc. Supramolecular complexes as photoactivated DNA cleavage agents
WO2006093891A2 (en) 2005-02-28 2006-09-08 The General Hospital Corporation Photosensitizers for targeted photodynamic therapy
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin
US8148360B2 (en) 2006-09-07 2012-04-03 Virginia Tech Intellectual Properties, Inc. Supramolecular metallic complexes exhibiting both DNA binding and photocleavage
US20110288023A1 (en) 2007-06-08 2011-11-24 The Regents Of The University Of California Office Of Technology Transfer Cancer drug delivery using modified transferrin
CA2739626A1 (en) 2010-05-07 2011-11-07 Ventria Bioscience Non-glycosylated transferrin expressed in monocots
EP2741775B1 (en) 2011-08-11 2017-01-04 Quest Pharmatech Inc. Polymeric nanoparticles for photosensitizers
RU2677855C2 (ru) * 2012-04-15 2019-01-22 Шерри МАКФАРЛЭНД Фотодинамические тиофены на основе металла и их применение
RU2682674C2 (ru) * 2013-03-15 2019-03-20 Шерри Энн МАКФАРЛЭНД Координационные комплексы на основе металлов в качестве фотодинамических соединений и их применение
CN104072607B (zh) * 2013-03-29 2019-01-15 中国科学院化学研究所 一种有机金属钌缀合蛋白及其制备方法与应用

Also Published As

Publication number Publication date
WO2016116859A1 (en) 2016-07-28
EP3247397B1 (en) 2021-05-19
EP3247397A4 (en) 2018-06-20
RU2742981C2 (ru) 2021-02-12
CN117159705A (zh) 2023-12-05
RU2017129587A3 (pt) 2019-02-21
CN107427579A (zh) 2017-12-01
CA2974329A1 (en) 2016-07-28
CA2974329C (en) 2018-10-02
US20160206653A1 (en) 2016-07-21
EP3247397A1 (en) 2017-11-29
US9737565B2 (en) 2017-08-22
RU2017129587A (ru) 2019-02-21

Similar Documents

Publication Publication Date Title
BR112017015499A2 (pt) ?composição, e, métodos para tratar uma condição associada com células hiperprolifereantes, e para destruir uma célula microbiana?
BR112015023568B8 (pt) Composto à base de metal como composto fotodinâmico
CY1120582T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CL2018002924A1 (es) Inhibidores de bromodominios
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112018011228A2 (pt) tratamentos de combinação e seus usos e métodos
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
WO2017182783A3 (en) Inactivation of dna repair as an anticancer therapy
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
EA201991622A1 (ru) Комплексная терапия для лечения рака
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
BR112014025702A2 (pt) compostos de tiofeno fotodinâmicos a base de metal e seus usos
MX2019011982A (es) Compuesto macrociclico y sus usos.
GEP20196950B (en) Imidazopyridazine compounds
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
MY194629A (en) Combination therapy
ZA201800931B (en) Selection of patients for combination therapy
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2021012894A (es) Compuestos ciclicos de fosfato.
BR112016029024A2 (pt) conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]